Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

• Glavni autori: Stijn Hentzen (Autor), Kathan Mehta (Autor), Raed Moh'd Taiseer Al-Rajabi (Autor), Anwaar Saeed (Autor), Joaquina Celebre Baranda (Autor), Stephen K. Williamson (Autor), Weijing Sun (Autor), Anup Kasi (Autor)
• Format: Knjiga
• Izdano: Open Exploration Publishing Inc., 2023-06-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior to the FDA approval of Lu-177 showed favorable outc...